Xact Kapitalforvaltning’s Iovance Biotherapeutics IOVA Stock Holding History

Xact Kapitalforvaltning’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$614K	Hold	20,500	–	–	0.01%	661
2019 Q4	$567K	Hold	20,500	–	–	0.01%	893
2019 Q3	$373K	Hold	20,500	–	–	0.01%	1094
2019 Q2	$503K	Hold	20,500	–	–	0.01%	918
2019 Q1	$195K	Hold	20,500	–	–	﹤0.01%	1396
2018 Q4	$181K	Buy	20,500 +7,600	+59%	+$73.3K	﹤0.01%	1450
2018 Q3	$145K	Hold	12,900	–	–	﹤0.01%	1543
2018 Q2	$165K	Buy	12,900 +2,600	+25%	+$38K	﹤0.01%	1568
2018 Q1	$174K	Buy	+10,300	New	+$156K	﹤0.01%	1502

Other funds holding IOVA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Xact Kapitalforvaltning's IOVA Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Iovance Biotherapeutics (IOVA) position steady in Q1 2020 at 20,500 shares worth $614K. The position accounts for 0.01% of the portfolio, ranked #661.

Xact Kapitalforvaltning first reported a position in IOVA in Q1 2018 and has held it in 9 quarters since. 219 funds tracked by Wall St. Rank hold IOVA as of Q1 2020.

Xact Kapitalforvaltning held 20,500 shares of Iovance Biotherapeutics worth $614K as of Q1 2020.
Xact Kapitalforvaltning left its Iovance Biotherapeutics share count unchanged in Q1 2020.
Iovance Biotherapeutics made up 0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #661 holding.
Xact Kapitalforvaltning first reported a position in Iovance Biotherapeutics in Q1 2018 and has held it in 9 quarters since.
219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.